# US 2026/0132121 A1 · Inhibitors of ripk2 and medical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0132121 A1
- Document ID: US20260132121A1
- Status: Published application
- Kind: A1
- Application number: 19/131,704
- Filed: 2023-11-22
- Published: 2026-05-14
- Earliest claimed: 2022-11-22
- Assignees: Odyssey Therapeutics, Inc.
- Applicants: Odyssey Therapeutics, Inc.
- Inventors: Chad VanHuis; Shifeng Pan; Dominik K. Koelmel; Robert Aversa; Clarke Taylor; Marta Wlodarska
- Web page: https://patentgrep.com/patent/US20260132121A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07B 59/002: {Heterocyclic compounds}
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D 451/06: Oxygen atoms
- C07D 487/08: Bridged systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 498/08: Bridged systems
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/65685: {the ring phosphorus atom being part of a phosphine oxide or thioxide}
- C07K 16/2839: {against the integrin superfamily}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.

## Claims

### Claim 1

A compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
R1a, R1b, and R1c are each independently selected from H, C1-6 alkyl, halogen, CN, and;
R2 is H or C1-3 alkyl;
R3 is selected from S(═O)2R5, halogen, 4- to 10-membered heterocyclyl, 5-12 membered heteroaryl, S(═O)(═NR6)(R7), QR7, C(═O)NR8R9, NH(C═O)R5, CN, NR8R9, P(═O)R8aR9a;
R4 is selected from H, halogen, C1-6 alkyl, and C1-6 alkoxy;
R5 is selected from C1-6 alkyl, NR10R11, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl;
R6 is selected from H, CN, and C1-6 alkyl;
R7 is selected from C1-6 alkyl, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl, 5-12 membered heteroaryl, or
R6 and R7 taken together with the nitrogen and sulfur atoms to which they are attached form 4- to 10-membered heterocyclyl;
Q is selected from O, S, —S(═O)—, and —C(═O)—;
R8 and R9 are each independently selected from H, C1-6 alkyl, C1-6 deuteroalkyl, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl, or
R8 and R9 taken together with the nitrogen atom to which they are attached form 4- to 10-membered heterocyclyl;
R8a and R9b are each independently C1-6 alkyl, or
R8a and R9a taken together with the phosphorus atom to which they are attached form 4- to 10-membered heterocyclyl;
R10 and R11 are each independently H or C1-6 alkyl, or
R10 and R11 taken together with the nitrogen to which they are attached form 4- to 10-membered heterocyclyl;
W is selected from a bond, O, NR2, O(C1-2 alkylene), NH(C1-2 alkylene), C1-2 alkylene, and C3-6 cycloalkylene;
X is a moiety represented by one of the following structural formulas:
Y1 is CH or N;
Y2 and Y3 are each independently CR4 or N;
U is CR12b or N;
Z is CR1b or N;
L, M, and J are each independently selected from N, O, or S, provided that two of L, M, and J are N;
R12 is selected from C3-6 alkyl, C3-6 cycloalkyl, C5-12 bridged bicyclic carbocyclyl, and 4- to 10-membered heterocyclyl;
R12a is selected from C1-6 alkyl, C1-6 deuteroalkyl, C3-6 cycloalkyl, C5-12 bridged bicyclic carbocyclyl, and 4- to 10-membered heterocyclyl;
R12b and R13 are each independently H or C1-6 alkyl;
and
is a single bond or a double bond,
wherein each C1-6 alkyl, C1-3 alkyl, C1-2 alkylene, C3-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C5-12 bridged bicyclic carbocyclyl, 5-12 membered heteroaryl, and 4- to 10-membered heterocyclyl is optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C1-6 deuteroalkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, (C1-6)alkylamino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 8-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently selected from hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl, and halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently selected from H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl, and di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.
provided that when Y2 is CH substituted with R4 and R4 is optionally substituted C1-6 alkoxy, W—R3 is not CN or optionally substituted C1-6 alkoxy; and
provided that when Y1, Y2 and Y3 are each CH, then W—R3 is not F.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is represented by structural formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
R1a, R1b, and R1c are each independently selected from H, C1-6 alkyl, halogen, and CN;
R2 is H or C1-3 alkyl;
R3 is selected from S(═O)2R5, halogen, 4- to 10-membered heterocyclyl, 5-12 membered heteroaryl, S(═O)(═NR6)(R7), QR7, C(═O)NR8R9, NH(C—O)R5, CN, NR8R9, P(═O)R8aR9a,
R4 is selected from H, halogen, C1-6 alkyl, and C1-6 alkoxy;
R5 is selected from C1-6 alkyl, NR10R11, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl;
R6 is selected from H, CN, and C1-6 alkyl;
R7 is selected from C1-6 alkyl, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl, 5-12 membered heteroaryl, or
R6 and R7 taken together with the nitrogen and sulfur atoms to which they are attached form 4- to 10-membered heterocyclyl;
Q is selected from O, S, —S(═O)—, and —C(═O)—;
R8 and R9 are each independently selected from H, C1-6 alkyl, C3-6 cycloalkyl, and 4- to 10-membered heterocyclyl, or
R8 and R9 taken together with the nitrogen atom to which they are attached form 4- to 10-membered heterocyclyl;
R8a and R9b are each independently C1-6 alkyl, or R8a and R9a taken together with the phosphorus atom to which they are attached form 4- to 10-membered heterocyclyl;
R10 and R11 are each independently H or C1-6 alkyl, or
R10 and R11 taken together with the nitrogen to which they are attached form 4- to 10-membered heterocyclyl;
W is selected from a bond, O, NR2, O(C1-2 alkylene), NH(C1-2 alkylene), and C1-2 alkylene;
X is a moiety represented by one of the following structural formulas:
Y1 is CH or N;
Y2 and Y3 are each independently CR4 or N;
U is CR12b or N;
Z is CR1b or N;
L, M, and J are each independently selected from N, O, or S, provided that two of L, M, and J are N;
R12 is selected from C3-6 alkyl, C3-6 cycloalkyl, C5-12 bridged bicyclic carbocyclyl, and 4- to 10-membered heterocyclyl;
R12a is selected from C1-6 alkyl, C3-6 cycloalkyl, C5-12 bridged bicyclic carbocyclyl, and 4- to 10-membered heterocyclyl;
R12b and R13 are each independently H or C1-6 alkyl;
and
is a single bond or a double bond,
wherein each C1-6 alkyl, C1-3 alkyl, C1-2 alkylene, C3-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C5-12 bridged bicyclic carbocyclyl, 5-12 membered heteroaryl, and 4- to 10-membered heterocyclyl is optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 8-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently selected from hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl, and halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently selected from H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl, and di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.
provided that when Y2 is CH substituted with R4 and R4 is optionally substituted C1-6 alkoxy, W—R3 is not CN or optionally substituted C1-6 alkoxy; and
provided that when Y1, Y2 and Y3 are each CH, then W—R3 is not F.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R3 is selected from 4- to 10-membered heterocyclyl, 5-10 membered heteroaryl, S(═O)2R5, —S(═O)(═NR6)(R7), and C(═O)NR8R9.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein W is selected from NH, N(C1-2 alkylene), O(C1-2 alkylene), and C1-2 alkylene.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein W is O.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein W is a bond.

### Claim 7 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein W is a C3-6 cycloalkylene.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is a 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 8-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently selected from hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl, and halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently selected from H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl, and di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R3 is a saturated 4- to 6-membered heterocyclyl.

### Claim 10 (depends on 8, 9)

The compound of claim 8 or 9, wherein R3 is substituted with oxo.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is a moiety represented by structural formula
wherein:
A is O or NR28, and
R28 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and 4- to 6-membered heterocyclyl, wherein each C1-6 alkyl, C3-6 cycloalkyl, and 4- to 6-membered heterocyclyl is optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 8-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently selected from hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl, and halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl, and di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is a moiety represented by one of the following structural formulas:
wherein R28 is H or C1-3 alkyl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is S(═O)2R5.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R5 is C1-6 alkyl.

### Claim 15 (depends on 13)

The compound of claim 13, wherein R5 is C1-3 alkyl.

### Claim 16 (depends on 13)

The compound of claim 13, wherein R5 is C3-6 cycloalkyl.

### Claim 17 (depends on 13)

The compound of claim 13, wherein R5 is 4- to 6-membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl or halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl or di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.

### Claim 18 (depends on 13)

The compound of claim 13, wherein R5 is NR10R11.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R10 and R11 are each independently C1-6 alkyl.

### Claim 20 (depends on 18)

The compound of claim 18, wherein R10 is H and R11 is C1-6 alkyl.

### Claim 21 (depends on 18)

The compound of claim 18, wherein R10 and R11 are each H.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is (R7)S(═O)(NR6).

### Claim 23 (depends on 22)

The compound of claim 22, wherein R6 is H, and R7 is C1-6 alkyl or C3-6 cycloalkyl.

### Claim 24 (depends on 22)

The compound of claim 22, wherein R6 and R7 taken together with the nitrogen and sulfur atoms to which they are attached form a 4- to 10-membered heterocyclyl.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is C(═O)NR8R9.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R8 is H and R9 is C1-3 alkyl.

### Claim 27 (depends on 25)

The compound of claim 25, wherein R8 and R9 are H.

### Claim 28 (depends on 25)

The compound of claim 25, wherein R8 and R9 are each independently C1-3 alkyl.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is selected from QR7, NH(C═O)R5, CN, and NR8R9.

### Claim 30 (depends on 29)

The compound of claim 29, wherein R3 is QR7.

### Claim 31 (depends on 30)

The compound of claim 30, wherein Q is O.

### Claim 32 (depends on 30)

The compound of claim 30, wherein Q is S.

### Claim 33 (depends on 30)

The compound of claim 30, wherein Q is —C(═O)—.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The compound of any one of claims 29-33, wherein R7 is C1-6 alkyl.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is halogen.

### Claim 36 (depends on 35)

The compound of claim 35, wherein R3 is F.

### Claim 37 (depends on 35)

The compound of claim 35, wherein R3 is Cl.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, wherein R3 is P(═O)R8aR9a.

### Claim 39 (depends on 38)

The compound of claim 38, wherein R8a and R9b are each independently C1-3 alkyl.

### Claim 40 (depends on 38)

The compound of claim 38, wherein R8a and R9a taken together with the phosphorus atom to which they are attached form 4- to 10-membered heterocyclyl.

### Claim 41 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Ia):

### Claim 42 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Ib):

### Claim 43 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Ic):

### Claim 44 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Id):

### Claim 45 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Ie):
wherein Hal is halogen.

### Claim 46 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (If):

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The compound of any one of claims 1-45, wherein R4 is H.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The compound of any one of claims 1-33 and 35-45, wherein R4 is C1-6 alkoxy.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, wherein X is a moiety represented by the following structural formula:

### Claim 50 (depends on 49)

The compound of claim 49, wherein R13 is H.

### Claim 51 (depends on 49)

The compound of claim 49, wherein R13 is C1-6 alkyl.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, wherein X is a moiety represented by the following structural formula:

### Claim 53 (depends on 52)

The compound of claim 52, wherein R13 is H.

### Claim 54 (depends on 52)

The compound of claim 52, wherein R13 is C1-6 alkyl.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, wherein X is a moiety represented by the following structural formula:

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, wherein X is a moiety represented by one of the following structural formulas:

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 1-48, wherein X is a moiety represented by one of the following structural formulas:

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-57, wherein R12 is C3-6 alkyl optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl, wherein
R14, R15, R18, R18a, R20, R20a, R24, and R27 are each independently hydrogen or C1-6 alkyl;
R16 and R17 are each independently hydrogen, C1-6 alkyl, hydroxy(C1-6)alkyl or halo(C1-6)alkyl;
R19 and R23 are each independently C1-6 alkyl or halo(C1-6)alkyl;
R21, R22, R25 and R26 are each independently H, C1-6 alkyl, C1-3 alkoxy(C1-6)alkyl, hydroxy(C1-6)alkyl, cyano(C1-6)alkyl, amino(C1-6)alkyl, C1-3 alkylamino(C1-6)alkyl or di(C1-3)alkylamino(C1-6)alkyl; or
R21 and R22 or R25 and R26, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from deuterium, oxo, F, Cl, Br, CN, OR14, SR15, NR16R17, S(O)R18, S(O)2R18a, NR19S(═O)R20, C(═O)OR20a, C(═O)NR21R22, NR23C(═O)R24, C(═S)NR25R26, C(═O)R27, C1-6 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, halo(C1-6)alkyl, C1-3 alkylsulfonylaminoalkyl, hydroxy(C1-6)alkyl, amino(C1-6)alkyl, cyano(C1-6)alkyl, C1-3 alkylcarbonylamino(C1-6)alkyl, C1-3 alkoxy, halo(C1-3)alkoxy, C1-6 alkoxy(C1-3)alkyl, C6-12 aryl, 4- to 10-membered heterocyclyl, and 5- to 12-membered heteroaryl.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-57, wherein R12 is selected is a moiety represented by one of the following structural formulas:

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1-57, wherein R12 is selected is a moiety represented by one of the following structural formulas:

### Claim 61 (depends on 60)

The compound of claim 60, wherein R12 is a moiety represented by structural formula

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 1-61, wherein R1a is halogen.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 1-61, wherein R1a is C1-3 alkyl.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 1-61, wherein R1a is selected from H, F, Cl, CH3, CHF2, CF3, and CD3.

### Claim 65 (depends on 64)

The compound of claim 64, wherein R1a is selected from F, CH3, and CHF2.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 1-65, wherein R1b is halogen.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 1-65, wherein R1b is C1-3 alkyl.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 1-65, wherein R1b is selected from H, F, Cl, CH3, CHF2, CF3, and CD3.

### Claim 69 (depends on 68)

The compound of claim 68, wherein R1b is selected from F, CH3, and CHF2.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 1-69, wherein R1c is H or halogen.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 1-69, wherein R1c is F.

### Claim 72 (depends on 1, 2)

The compound of any claim 1 or 2, wherein the compound is represented by structural formula (Ig):

### Claim 73 (depends on 1, 2)

The compound of any one of claim 1 or 2, wherein the compound is represented by structural formula (Ih), (Ii), or (Ij):

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The compound of any one of claims 1-73, wherein Y′ is CH.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The compound of any one of claims 1-73, wherein Y′ is N.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The compound of any one of claims 1-72, wherein Z is CH.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The compound of any one of claims 1-72, wherein Z is N.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The compound of any one of claims 1-77, wherein R2 is H.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The compound of any one of claims 1-77, wherein R2 is C1-3 alkyl.

### Claim 80 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Ik):
wherein R5 is C1-3 alkyl.

### Claim 81 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (II):
wherein R′ is H or C1-3 alkyl.

### Claim 82 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (Im):
wherein R29 is H or C1-3 alkyl.

### Claim 83 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is represented by structural formula (In):
wherein:
R1a is selected from C1-3 alkyl, halogen, and H;
R1b and R4 is each independently halogen or H;
R1c is selected from C1-3 haloalkyl, halogen, and H; and
R9 is H or C1-3 alkyl.

### Claim 84 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is selected from the compounds in Table 1.

### Claim 85 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is selected from the compounds in Table 2.

### Claim 86 (depends on 1, 2)

The compound of claim 1 or 2, wherein the compound is selected from the compounds in Table 3.

### Claim 87 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

A pharmaceutical composition comprising a compound of any one of claims 1-86 and a pharmaceutically acceptable excipient.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

A method of treating a disease or disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-86 or a pharmaceutical composition of claim 87, wherein the disease or disorder is selected from an inflammatory disease, autoimmune disease, granulomatous disease, cancer, and neurodegenerative disease.

### Claim 89 (depends on 88)

The method of claim 88, wherein the disease or disorder is an inflammatory disease.

### Claim 90 (depends on 89)

The method of claim 89, wherein the inflammatory disease is selected from uveitis, interleukin-1 converting enzyme fever syndrome, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, inflammatory bowel disorder (IBD), ischemia reperfusion injury in a solid organ transplant, sepsis, liver disease, allergic disease, and graft versus host disease.

### Claim 91 (depends on 89)

The method of claim 89, wherein the inflammatory disease is an IBD.

### Claim 92 (depends on 91)

The method of claim 91, wherein the IBD is selected from ulcerative colitis, Crohn's disease, early-onset IBD, and extraintestinal IBD.

### Claim 93 (depends on 89)

The method of claim 89, wherein the inflammatory disease is selected from rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, α-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease.

### Claim 94 (depends on 88)

The method of claim 88, wherein the disease or disorder is an autoimmune disease.

### Claim 95 (depends on 94)

The method of claim 94, wherein the autoimmune disease is selected from systemic lupus
erythematosus, lupus nephritis, psoriasis, immune thrombocytopenia purpura, and multiple sclerosis.

### Claim 96 (depends on 88)

The method of claim 88, wherein the disease or disorder is a granulomatous disease.

### Claim 97 (depends on 96)

The method of claim 96, wherein the granulomatous disease is selected from sarcoidosis,
Blau syndrome, Wegner's granulomatosis, Behcet's disease, and interstitial pulmonary disease.

### Claim 98 (depends on 88)

The method of claim 88, wherein the disease or disorder is a cancer.

### Claim 99 (depends on 98)

The method of claim 98, wherein the cancer is selected from leukemia, breast cancer, brain cancer, colorectal cancer, head and neck cancer, melanoma, pancreatic cancer, prostate cancer, ovarian cancer, renal cancer, and lung cancer.

### Claim 100 (depends on 88)

The method of claim 88, wherein the disease or disorder is a neurodegenerative disease.

### Claim 101 (depends on 100)

The method of claim 100, wherein the neurodegenerative disease is selected from Alzheimer's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's Disese), Parkinson's disease, multiple sclerosis, diabetic neurophathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cerebral ischemia, a prion disorder, dementia, corticobasal degeneration, progressive supranuclear palsy, spinocerebellar atrophies, brain injury, and spinal cord injury.

### Claim 102 (depends on 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 88-101, further comprising administering a therapeutically effective amount of a second agent.

### Claim 103 (depends on 102)

The method of claim 102, wherein the second agent is an anti-inflammatory agent or an anti-autoimmune agent.

### Claim 104 (depends on 102)

The method of claim 102, wherein the second agent is selected from anti-TNF agent, anti-IL-23 agent, anti-integrin agent, and JAK inhibitor.

### Claim 105 (depends on 104)

The method of claim 104, wherein the second agent is anti-TNF agent.

### Claim 106 (depends on 104)

The method of claim 104, wherein the second agent is anti-IL-23 agent.

### Claim 107 (depends on 104)

The method of claim 104, wherein the second agent is anti-integrin agent.

### Claim 108 (depends on 104)

The method of claim 104, wherein the second agent is JAK inhibitor.

### Claim 109 (depends on 102, 103, 104, 105, 106, 107, 108)

The method of any one of claims 102-108, wherein the second agent and the compound are administered together in a single pharmaceutical composition.

### Claim 110 (depends on 102, 103, 104, 105, 106, 107, 108)

The method of any one of claims 102-108, wherein the second agent and the compound are administered separately.
